TargetDihydroorotate dehydrogenase (quinone), mitochondrial(Homo sapiens (Human))
Bayer Aktiengellschaft
US Patent
Bayer Aktiengellschaft
US Patent
Affinity DataIC50: 0nMAssay Description:The enzymatic assay couples DHODH activity with bleaching of the dye 2,6-dichlorophenolindophenol (DCIP) (Knecht and Loffler, 1998; Miller et al., 19...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0300nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0700nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0900nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0900nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.110nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.110nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.110nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.130nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.130nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.140nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 0.140nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.150nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.150nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.160nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.160nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.160nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.170nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.210nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.210nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.210nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.210nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.220nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase kinase 1(Homo sapiens (Human))
Bristol Myers Squibb
Curated by ChEMBL
Bristol Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 0.220nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged HPK1 (1 to 346 residues) expressed in baculovirus infected Sf9 cells using NH2-fluorescein-RFAR...More data for this Ligand-Target Pair
Affinity DataIC50: 0.220nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.230nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.230nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.230nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.230nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.240nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.25nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.260nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [L858R,T790M,C797S](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.260nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [L858R,T790M,C797S](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.270nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.270nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.280nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase kinase 1(Homo sapiens (Human))
Bristol Myers Squibb
Curated by ChEMBL
Bristol Myers Squibb
Curated by ChEMBL
Affinity DataIC50: 0.280nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged HPK1 (1 to 346 residues) expressed in baculovirus infected Sf9 cells using NH2-fluorescein-RFAR...More data for this Ligand-Target Pair
Affinity DataIC50: 0.280nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.290nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Arvinas Operations
US Patent
Arvinas Operations
US Patent
Affinity DataIC50: 0.290nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Affinity DataIC50: 0.290nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in th...More data for this Ligand-Target Pair